Characterization of the Fc gamma receptor on human platelets.
IgG-containing immune complexes may play a role in the immune destruction of human platelets by interacting with an Fc gamma receptor on the platelet surface. We studied the platelet Fc gamma receptor and characterized its interaction with IgG ligand and anti-Fc gamma receptor monoclonal antibodies. Oligomers of IgG, but not monomeric IgG, bound to platelets and the number of binding sites was significantly increased at low ionic strength. Ligand-binding studies indicated that normal human platelets express a single Fc gamma receptor (Fc gamma RII) with 8559 +/- 852 sites per cell, Kd = 12.5 +/- 1.7 X 10(-8) M using trimeric IgG. Results of studies with bivalent and Fab monoclonal anti-Fc gamma RII were consistent with each Fc gamma receptor expressing two epitopes recognized by the antibody. The number of Fc gamma binding sites and affinity of binding were unchanged by the presence of 2.0 mM Mg2+ or 10 micrograms/ml cytochalasin B. Platelet stimulation with thrombin or ADP in the presence of fibrinogen also did not alter the number of Fc gamma binding sites or the affinity of binding. However, platelets preincubated with 5 microM dexamethasone expressed a decreased number of Fc gamma binding sites as well as decreased IgG-dependent platelet aggregation. Platelets from patients with Glanzmann's thrombasthenia and from patients with the Bernard Soulier syndrome expressed a normal number and affinity of Fc gamma binding sites. The data suggest that platelet Fc gamma RII binding of trimeric IgG occurs independent of actin filament interaction, Mg2+, ADP, or thrombin and does not require GPIIb/IIIa or GPIIb/IIIa-fibrinogen interaction. Furthermore, this receptor appears to be normally expressed on GPIb-deficient platelets and susceptible to modulation by glucocorticoids. Finally, the Fc gamma-binding protein was isolated from whole platelets as a 220-kDa protein which upon reduction dissociates into 50,000 Mr subunits.
King
M
M
University of Pennsylvania Graduate Group in Immunology, University of Pennsylvania School of Medicine, Philadelphia 19104.
McDermott
P
P
Schreiber
A D
AD
D000328:Adult; D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation / Q000302:isolation & purification / Q000502:physiology*; D001606:Bernard-Soulier Syndrome / Q000378:metabolism; D001792:Blood Platelets / Q000502:physiology*; D015153:Blotting, Western; D002413:Cations, Divalent / Q000494:pharmacology; D003571:Cytochalasin B / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism*; D008875:Middle Aged; D008970:Molecular Weight; D009994:Osmolar Concentration; D010974:Platelet Aggregation / Q000187:drug effects; D010980:Platelet Membrane Glycoproteins / Q000302:isolation & purification / Q000502:physiology*; D011961:Receptors, Fc / Q000302:isolation & purification / Q000502:physiology*; D017452:Receptors, IgG; D013915:Thrombasthenia / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D002413:Cations, Divalent; D007074:Immunoglobulin G; D010980:Platelet Membrane Glycoproteins; D011961:Receptors, Fc; D017452:Receptors, IgG; D003571:Cytochalasin B; D003907:Dexamethasone